Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919176 · ClinicalTrials.gov registry record · Early Phase 1
Brown Fat Activation Study
A Early Phase 1 study, sponsored by Philip Kern.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
NCT02919176: Completed Early Phase 1 study, sponsored by Philip Kern.
NCT02919176 is a Early Phase 1 study that has completed, run by Philip Kern. The registered enrollment target is 39 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02919176, a Early Phase 1 study, has completed, sponsored by Philip Kern.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open lable, pilot study in which the investigator will research the effect of two FDA approved drugs, Mirabegron and Pioglitazone on fat tissue. Pioglitazone is drug approved by the FDA for the treatment of diabetes and Mirabegron is a drug that is approved by the FDA for the treatment of overactive bladder. These drugs are not approved by the FDA for the purposes being studied in this research. Therefore, the way in which the investigator intends to use them in this study are considered investigational.
Primary Outcome
Beige adipose tissue markers will be evaluated at baseline, and after treatment with mirabegron, pioglitazone, or both drugs
Interventions
- DRUG Pioglitazone
- DRUG Mirabegron
- DRUG Mirabegron and Pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2019-02-04 |
| Phase | Early Phase 1 |
What the finished NCT02919176 record still lists
NCT02919176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 3 interventions - of which Pioglitazone is the first listed.
NCT02919176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02919176 about?
NCT02919176 is a clinical study titled "Brown Fat Activation Study". This is an open lable, pilot study in which the investigator will research the effect of two FDA approved drugs, Mirabegron and Pioglitazone on fat tissue. Pioglitazone is drug approved by the FDA for the treatment of diabetes and Mirabegron is a drug that is approved by the FDA for the treatment o...
What is the current status of trial NCT02919176?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2016-09-01. Estimated completion is 2019-02-04.
What interventions are being tested in trial NCT02919176?
The interventions under investigation include: Pioglitazone (DRUG), Mirabegron (DRUG), Mirabegron and Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT02919176?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02919176's enrollment target sits among peer trials
39 689th of 2000 higher than 1,302 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI